AGMB
Agomab Therapeutics NV
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Agomab Therapeutics NV
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Agomab Therapeutics NV
7.15
No N-PORT holders.
No thesis.
Expected move
No implied move.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | EQT Fund Management S.a r.l.EQT Fund Management S.a r.l. | $66.7M | 19.81% | 0.00% | |
| 2 | SanofiSanofi | $36.1M | 10.72% | 0.00% | |
| 3 | Redmile GroupRedmile | $35.5M | 10.53% | +1649.71% | |
| 4 | Cormorant Asset ManagementCormorant | $32.0M | 9.50% | 0.00% | |
| 5 | TCG Crossover ManagementTCG Crossover | $26.7M | 7.91% | 0.00% | |
| 6 | Federated InvestorsFederated Investors | $21.0M | 6.23% | 0.00% | |
| 7 | Nantahala Capital ManagementNantahala | $20.4M | 6.04% | +30.68% | |
| 8 | Casdin CapitalCasdin Capital | $20.1M | 5.97% | 0.00% | |
| 9 | Andera PartnersAndera Partners | $20.0M | 5.93% | 0.00% | |
| 10 | FMRFMR | $18.9M | 5.62% | 0.00% | |
| 11 | Standard Life AberdeenStandard Life Aberdeen | $11.0M | 3.26% | +19.65% | |
| 12 | Perceptive AdvisorsPerceptive | $7.8M | 2.31% | 0.00% | |
| 13 | Samsara BioCapitalSamsara BioCapital | $7.8M | 2.31% | 0.00% | |
| 14 | SirenSiren | $5.3M | 1.58% | 0.00% | |
| 15 | Orbimed AdvisorsOrbimed | $2.5M | 0.74% | new | |
| 16 | PfizerPfizer | $1.0M | 0.31% | 0.00% | |
| 17 | Alps AdvisorsAlps | $648,792 | 0.19% | new | |
| 18 | Bellevue GroupBellevue | $639,239 | 0.19% | −1.50% | |
| 19 | Seven Grand ManagersSeven Grand Managers | $617,848 | 0.18% | −76.20% | |
| 20 | Sectoral Asset ManagementSectoral | $564,630 | 0.17% | 0.00% | |
| 21 | Burkehill Global ManagementBurkehill Global | $454,300 | 0.13% | 0.00% | |
| 22 | Quadrature CapitalQuadrature Capital | $265,584 | 0.08% | new | |
| 23 | Two Sigma InvestmentsTwo Sigma | $234,575 | 0.07% | +26.90% | |
| 24 | HRT FinancialHRT Financial | $222,000 | 0.07% | −28.03% | |
| 25 | Goldman Sachs GroupGoldman Sachs | $153,164 | 0.05% | −66.98% |
34 managers report $337.0M of Agomab Therapeutics on form 13F for the quarter ended Jun 30 '26. 9 of them hold 80% of it; EQT Fund Management S.a r.l. is largest at 19.81%.